ResearchHub Logo
Currency
Display format
RSCUSD

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Authors
Patrick FordeCécile DorangeNicolas Girard
Journal
New England Journal of Medicine
Published
April 11, 2022

Abstract

Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have shown promising clinical activity; however, data from phase 3 trials are needed to confirm these findings.

Supporters

Support the authors with ResearchCoin

Topics

DOI

10.1056/nejmoa2202170

License

Unknown License
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lun... | ResearchHub